Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02409732
Recruitment Status : Completed
First Posted : April 7, 2015
Results First Posted : October 23, 2018
Last Update Posted : October 23, 2018
Sponsor:
Collaborator:
DUSA Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Michael S. Chapman, Dartmouth-Hitchcock Medical Center

Brief Summary:
To evaluate the safety and efficacy of PDT with blue light and topical Levulan in the treatment of actinic cheilitis.

Condition or disease Intervention/treatment Phase
Actinic Cheilitis Drug: aminolevulinic acid hydrochloride Procedure: Photodynamic therapy with blue light Phase 4

Detailed Description:

The study will consist of a screening visit, up to three scheduled treatments, and two scheduled office visits. There can be a three-day window period for each scheduled visit in order to accommodate the subject's schedule and unforeseen scheduling conflicts.

  1. Visit 1 (Screening): Subjects can be screened for the study up to two weeks before Visit 2 (Baseline). During screening, the study will be reviewed, written informed consent obtained, and eligibility confirmed. If applicable, the washout from prohibited medications or treatments will be determined at this visit.
  2. Visit 2 (Baseline): Following signed, written informed consent and confirmation of eligibility, all subjects will have their lips photographed. Medical history, dermatologic exam, urine pregnancy test (if applicable), review of concomitant medications, clinical evaluations, and tolerability assessments will be performed at this visit. Study medication application to clean skin will be followed by a 90 minute incubation period under occlusion. Subsequently, patients will be exposed to blue light therapy for 16 minutes and 40 seconds. Post-therapy assessments will be performed afterwards, as well as education on appropriate sun protection methods.
  3. Visits 3-4: Subjects will return every six weeks for up to two additional treatments. Treatment will be discontinued once the patient has achieved clinical clearance. Tolerability assessments, study medication application, blue light therapy, post-therapy assessments, and photographs will be performed.
  4. Visit 5-6 (End of Study): Subjects will return 12 and 24 weeks after the last treatment for clinical evaluations, tolerability assessments, and photographs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
Study Start Date : April 2015
Actual Primary Completion Date : July 2017
Actual Study Completion Date : July 2017


Arm Intervention/treatment
Experimental: PDT
PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments
Drug: aminolevulinic acid hydrochloride
Other Names:
  • Levulan
  • aminolevulinic acid HCl

Procedure: Photodynamic therapy with blue light
Other Names:
  • PDT with blue light
  • PDT




Primary Outcome Measures :
  1. Number of Participants With a Change in Clearance From Baseline [ Time Frame: Visit 2 (Baseline) to Visit 5 or 6 (Week 24 or 36) ]
    Clearance will be estimated clinically as minimal (0%-25%), mild (26%-50%), moderate (51%-75%), good (76%-99%), or complete (100%). Results will also be evaluated by comparing photographs before and immediately after treatments, and 12 and 24 weeks after the last treatment.


Secondary Outcome Measures :
  1. Average Change in Participant Reported Pain [ Time Frame: Baseline to Week 36 ]
    Subject reported pain before, during and after blue light illumination was documented using a Visual Analogue Scale (VAS) from 0 (no pain) to 10 (worst pain imaginable). The maximum change in pain is 10 for each occurrence (pain before compared to during treatment and pain during compared to after treatment). This is multiplied by the number of subjects and then divided by the number of treatments to generate the range. The summation of the change between subject reported pain prior to compared to during blue light treatment was divided by the total number of treatments to obtain the average value. The summation of the change between subject reported pain during compared to after blue light treatment was divided by the total number of treatments to obtain the average value.

  2. Average Change in Local Skin Reactions to Blue Light Treatment [ Time Frame: Baseline to Week 36 ]
    Assessments of swelling, erythema, and flaking/scaling were conducted after each treatment and two days post-treatment using a five-point ordinal scale (0: none to 4: severe). The average change in swelling, erythema and flaking/scaling after each treatment and two days post treatment were divided by the 50 total treatments to obtain the average value.

  3. The Number of Participants Who Developed a Local Skin Reaction to Blue Light Treatment: Vesiculation/Pustulation, Erosion/Ulceration, Crusting and Hyperpigmentation [ Time Frame: Baseline to Week 36 ]
    Assessments of vesiculation/pustulation, erosion/ulceration, and crusting were conducted immediately after each blue light treatment using a five-point ordinal scale (0: none to 4: severe). The presence or absence of hyperpigmentation in the treatment area was also documented after each treatment visit. The total number of participants who developed a local skin reaction is documented.

  4. Number of Participants With Adverse Events [ Time Frame: Baseline to Week 36 ]
    Evaluation of any reported local or systemic events outside the treatment area and other than those specified under local skin reactions or PDT reactions.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must be able to understand and voluntarily sign an informed consent form
  • Must be male or female ≥ 18 years of age at the time of consent
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Must have a diagnosis of actinic cheilitis by histopathological evaluation of biopsy specimen or clinical presentation

Exclusion Criteria:

  • Inability to provide voluntarily consent or mentally incompetent
  • Active herpes labialis lesions
  • Subjects with any condition which places the subject at unacceptable risk if he/she were to participate in the study, or confounds the ability to interpret data from the study
  • Subjects with any other skin condition that might affect the evaluation of the study disease
  • Pregnant or breastfeeding female subjects
  • Subjects who have used any investigational medication within one month prior to study entry
  • Subjects who have been previously exposed to PDT and/or topical Levulan therapy for the treatment of actinic cheilitis
  • Subjects who have used local therapy (e.g. cryotherapy) or topical treatment (e.g. 5% fluorouracil) within three months of study entry
  • Subjects who have used an oral photosensitizing drug (e.g. Declomycin) within six months of study entry
  • Subjects who are currently using photosensitizing agents (e.g. thiazides, tetracyclines, fluoroquinolones, phenothiazines, and sulfonamides) because of the risk of augmented photosensitivity
  • Subjects who are frequently exposed to ultraviolet radiation (e.g. lifeguards, construction workers, frequent sunbed users, etc.)
  • Subjects with a history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins, or photodermatosis
  • Subjects with a known hypersensitivity to Levulan
  • Subjects who are immunocompromised

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02409732


Locations
Layout table for location information
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03766
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
DUSA Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Michael S Chapman, MD Dartmouth-Hitchcock Medical Center
  Study Documents (Full-Text)

Documents provided by Michael S. Chapman, Dartmouth-Hitchcock Medical Center:
Publications:
Layout table for additonal information
Responsible Party: Michael S. Chapman, Staff Physician, Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT02409732    
Other Study ID Numbers: D15043 28525
First Posted: April 7, 2015    Key Record Dates
Results First Posted: October 23, 2018
Last Update Posted: October 23, 2018
Last Verified: October 2018
Keywords provided by Michael S. Chapman, Dartmouth-Hitchcock Medical Center:
Actinic cheilitis
Photodynamic therapy
Levulan
Blue light
Additional relevant MeSH terms:
Layout table for MeSH terms
Cheilitis
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents